If you are not able to view this e-mail properly, please click here to view it online
World Pharma Today Maqazine
World Pharma Today Linkedin Page World Pharma Today Facebook Page World Pharma Today Twitter Page DOWNLOAD
Click here to subscribe to our Magazine
World Courier
Latest Articles
Oracle's Unified Cloud Platform Promises to Shorten Clinical Trials

Oracle's Unified Cloud Platform Promises to Shorten Clinical Trials

Oracle’s Clinical One Platform will enable pharmaceutical companies to manage every trial function from randomizing patient participants and collecting and analyzing data to tracking budgets and ensuring trial safety from a single user interface. The process of standing up clinical trials has come...


ChargePoint Technology Reinforces Asia Presence withGrowth in China and Japan

Powder containment and aseptic transfer valve specialist, ChargePoint Technology has achieved triple-digit growth in key Asian markets and will be exhibiting its sterile and highly potent handling...


Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, announced it received clearance from the FDA to initiate the first Phase 1 clinical trial...

Latest Press Releases
Aptar Pharma's Preservative-Free Multidose Dispenser

Aptar Pharma's Preservative-Free Multidose Dispenser Approved for Anti-Allergy Treatment by French Regulatory Agency ANSM

Aptar Pharma's innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the approved delivery device for Bausch+Lomb'sLevofree Multidose in France. This marks the first approval by the French National ANSM for Aptar Pharma's Ophthalmic Squeeze...


Aquinnah Pharmaceuticals Receives $3.4M Grant from NINDS To Advance New Therapies for ALS

Aquinnah Pharmaceuticals announced that it has been awarded $3.4 million from the National Institute of NINDS in a competing grant to advance novel therapeutic drug candidates towards the clinic...


Processa Pharmaceuticals Receives Orphan Designation Status For PCS499 In Necrobiosis Lipoidica From The FDA

Processa Pharmaceuticals, Inc announced hat the U.S. FDA has granted orphan-drug designation to its leading clinical compound PCS499 for treatment of Necrobiosis Lipoidica (NL).


For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2018 / Editorial Calender please click here

For the latest visit: www.worldpharmatoday.com

World Pharma Today